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Abstract
Background: Depression is associated with an unusually high rate of aging-related illnesses and early mortality. One aspect
of ‘‘accelerated aging’’ in depression may be shortened leukocyte telomeres. When telomeres critically shorten, as often
occurs with repeated mitoses or in response to oxidation and inflammation, cells may die. Indeed, leukocyte telomere
shortening predicts early mortality and medical illnesses in non-depressed populations. We sought to determine if
leukocyte telomeres are shortened in Major Depressive Disorder (MDD), whether this is a function of lifetime depression
exposure and whether this is related to putative mediators, oxidation and inflammation.
Methodology: Leukocyte telomere length was compared between 18 unmedicated MDD subjects and 17 controls and was
correlated with lifetime depression chronicity and peripheral markers of oxidation (F2-isoprostane/Vitamin C ratio) and
inflammation (IL-6). Analyses were controlled for age and sex.
Principal Findings: The depressed group, as a whole, did not differ from the controls in telomere length. However, telomere
length was significantly inversely correlated with lifetime depression exposure, even after controlling for age (p,0.05).
Average telomere length in the depressed subjects who were above the median of lifetime depression exposure ($9.2
years’ cumulative duration) was 281 base pairs shorter than that in controls (p,0.05), corresponding to approximately
seven years of ‘‘accelerated cell aging.’’ Telomere length was inversely correlated with oxidative stress in the depressed
subjects (p,0.01) and in the controls (p,0.05) and with inflammation in the depressed subjects (p,0.05).
Conclusions: These preliminary data indicate that accelerated aging at the level of leukocyte telomeres is proportional to
lifetime exposure to MDD. This might be related to cumulative exposure to oxidative stress and inflammation in MDD. This
suggest that telomere shortening does not antedate depression and is not an intrinsic feature. Rather, telomere shortening
may progress in proportion to lifetime depression exposure.
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Introduction
Major depressive disorder (MDD) is associated with a
significantly increased risk of developing serious medical illnesses
that are more commonly seen with advanced age, such as diabetes,
cardiovascular disease, immune impairments, stroke, dementia,
osteoporosis, diabetes and metabolic syndrome [1,2,3,4,5] and of
dying significantly earlier (even after accounting for socio-
demographic factors, suicide and risk factors such as smoking,
alcohol and physical illness) [6,7,8,9,10]. Indeed, major depression
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has been likened to a state of ‘‘accelerated aging,’’ with an
increased incidence of aging-related illnesses [1,8,11,12,13,14,15,
16,17,18,19,20,21,22]. Various explanations for a prematurely
aged phenotype in depression have been proposed, such as the
‘‘glucocorticoid cascade’’ hypothesis [23,24] and ‘‘allostatic load’’
[25], as well as an unhealthy lifestyle or environment. In this study,
we explored the additional (and not mutually exclusive) possibility
that ‘‘accelerated aging’’ in depression occurs at the level of
telomeres, as manifest in blood leukocytes. Further, we hypoth-
esized that such changes are directly correlated with cumulative
lifetime exposure to depression and are related to specific cytotoxic
biochemical mediators, such as pro-inflammatory cytokines and
oxidative stressors, which are often elevated in depression.
Telomeres are deoxyribonucleic acid (DNA)-protein complexes
that cap the ends of the linear chromosomal DNA, protecting the
genome from damage. In mitotic cells, telomeres can shorten with
each division, unless this can be counteracted or reversed by the
telomere-lengthening enzyme, telomerase [26,27]. When telomer-
ic DNA reaches a critically short length, as in cells undergoing
repeated mitotic divisions (e.g., leukocytes [28] and stem cells
[29,30,31,32,33]), cells become susceptible to senescence or
apoptosis [26,34]. Even in non-dividing cells, telomere shortening
has been associated with cytotoxic stressors such as oxidative
stress, which preferentially damages telomeric DNA compared
with non-telomeric DNA, and chronic inflammation
[35,36,37,38]. Such enhanced telomere shortening also increases
cellular susceptibly to apoptosis and death [33]. Telomere length is
emerging as a prognostic marker of disease risk and a robust
indicator of human ‘‘biological age’’ (as distinguished from
chronological age). It may represent a cumulative log of factors
such as the number of cell divisions and of exposure to cytotoxic
processes such as excessive oxidation and inflammation
[34,35,38,39,40,41,42]. Several recent studies in non-depressed
populations have demonstrated an inverse relationship between
leukocyte telomere length and the risk of current and future
medical illnesses (such as cardiovascular and infectious diseases
and dementia) and early death [42,43,44,45,46,47,48,49,50,
51,52,53,54]. Accelerated telomere shortening in individuals with
MDD could help explain the increased medical morbidity seen in
depression [8,40,46,55,56,57].
In addition to biochemical stressors such as oxidation and
inflammation, chronic psychological stress is also associated with
shortened telomeres [58,59]. For example, healthy chronically
stressed individuals (e.g., maternal caregivers of chronically ill
children and family caregivers of demented individuals) showed
significantly shorter leukocyte telomere length compared to age-
matched controls [58,59], and in one study, telomere length was
inversely correlated with the chronicity of caregiving (i.e., women
with greater cumulative duration of caregiving stress had shorter
telomeres) [58]. This is consistent with the hypothesis that
telomere shortening develops over time in proportion to
cumulative exposure to the stressors. The difference in mean
telomere base pairs (bp) between the two groups in that study
suggested approximately 9–17 years of accelerated biological aging
in the stressed, compared to the non-stressed, women [58]. In the
first study of telomere length in affective illnesses, including MDD,
subjects also had significantly shortened leukocyte telomere length
compared to controls, with an estimated acceleration of biological
cell aging of over 10 years (average telomere shortening = 660 bp)
[55]. That study utilized an extremely chronically ill population
(average cumulative lifetime duration of illness = 31.8611.2 [SD]
years). To the extent telomere length reflects cumulative exposure
to depression and cytotoxic factors, telomere length should be
inversely correlated with the lifetime chronicity of depression, and
therefore, extrapolation of findings from that study to individuals
with less chronic major depression may not be possible. A second
study examined leukocyte telomere shortening in major depression
and also found shortened telomeres [60], but it did not report the
chronicity of depression in their sample. A very recent study also
found shortened leukocyte telomeres in MDD (although various
psychiatric, neurological and somatic disorders were not excluded
in their sample), with an average shortening of 350 bp [61],
representing approximately 6–8 years of ‘‘accelerated aging.’’ In
that study, average telomere length was not related to lifetime
depression history, as assessed by the time from the first onset of
MDD through the time of the present assessment, but intervening
periods of time that the subjects were not depressed were not
excluded in that assessment. In the present study, to test effects of
depression status and chronicity on cell aging, we evaluated
depressed individuals across a broad range of depression
chronicity and assessed chronicity as the estimated time actually
spent in depressive episodes.
In addition to investigating telomere length in depression, we
were interested in assessing biological factors associated with
telomere shortening. Since depression is often associated with
increased oxidative stress [57,62,63,64,65,66,67] and with a pro-
inflammatory milieu [4,68,69,70,71,72], we reasoned that oxida-
tive stress and inflammation might contribute to shortened
telomeres in depression, just as they are believed to do in certain
medical illnesses and in preclinical models [36,38,41,46,57,
73,74,75,76,77,78]. We hypothesized that depressed individuals
would have shorter leukocyte telomeres than matched controls,
that telomere length would be inversely correlated with cumulative
lifetime exposure to depression, and that telomere length would be
inversely correlated with oxidative stress and inflammatory
markers.
Methods
Ethics Statement
Subjects gave written informed consent to participate in this
study, which was approved by the University of California, San
Francisco (UCSF) Committee on Human Research (CHR).
Objectives
To determine whether leukocyte telomeres are shortened in
individuals with Major Depressive Disorder (MDD), whether this
is a function of depression chronicity and whether this is related to
putative mediators, oxidation and inflammation.
Participants
Eighteen subjects with MDD, diagnosed with the Structured
Clinical Interview for DSM-IV-TR (SCID) [79], and 18
individually-matched healthy controls (matched by sex, ethnicity
and age 63 years) were recruited. One healthy control had an
inadequate blood sample collection, leaving 18 depressed subjects
and 17 healthy controls with usable data. Depressed subjects were
all outpatients; they and the controls were recruited by fliers,
bulletin board notices, Craigslist postings, newspaper ads and, in
the case of depressed subjects, clinical referrals. Subjects were paid
for their participation. SCID diagnostic interviews were conducted
by an experienced clinical psychologist and were clinically verified
by a separate psychiatric interview with a Board-certified
psychiatrist. Depressed subjects with psychosis or bipolar histories
were excluded, although co-morbid anxiety disorders were
allowed when the depressive diagnosis was considered to be the
primary diagnosis. Subjects with Post-Traumatic Stress Disorder
Telomere Length in Chronic Major Depression
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(PTSD) were excluded, since PTSD may have important
differences in stress hormone regulation [80]. Seven of the
depressed subjects had co-morbid anxiety diagnoses as follows:
three with generalized anxiety disorder, two with obsessive-
compulsive disorder, two with binge eating disorder (one of whom
was in remission) and one with social anxiety disorder. Healthy
controls were also screened with the SCID, and were required to
have no present or past history of any DSM-IV Axis I or Axis II
diagnosis. Potential subjects were excluded if they met SCID
criteria for alcohol or substance abuse within 6 months of entering
the study. Subjects in both groups were medically healthy (assessed
by physical examination, review of systems and screening
laboratory tests), had no acute illnesses or infections, and had
not had any vaccinations within 6 weeks of entering the study. All
subjects (depressed and control) were free of any psychotropic
medications, including antidepressants, antipsychotics and mood
stabilizers, as well as any hormone supplements, steroid-containing
birth control or other interfering medications (e.g. statins) or
Vitamin supplements above the U.S. Recommended Daily
Allowances (e.g. Vitamin C, 90 mg/day), for a minimum of 6
weeks before entry into the study (with the exception of short-
acting sedative-hypnotics, as needed, up to a maximum of 3 times
per week, but none within one week prior to testing).
Procedures
Subjects were admitted as outpatients to the UCSF Clinical and
Translational Science Institute’s Clinical Research Center at 8:00
am, having fasted (except water) since 10:00 pm the night before.
Before proceeding with testing, all subjects were required to test
negative on a urine toxicology screen (measuring the presence of
abused drugs) and, in women of child-bearing capacity, a urine
pregnancy test. After the subjects had sat quietly for 45 minutes,
blood samples were obtained for leukocyte telomere length,
oxidative stress markers (F2-isoprostanes and the anti-oxidant,
Vitamin C) and inflammation (IL-6). Whole blood was drawn for
the telomere length assay, and buffy coat was saved for leukocyte
telomere length assay. DNA was prepared from whole blood using
commercially available reagents (Gentra Puregene Blood Kit,
Qiagen, Valencia, CA). Blood for the F2-isoprostane assay was
collected into EDTA tubes with no vacuum, and blood for the
Vitamin C assay was collected into foil wrapped serum separator
tubes. Blood for IL-6 assay was collected into serum separator
tubes.
Severity of depression in the depressed subjects was ascertained
with the observer-rated 17-item Hamilton Depression Rating
Scale (HDRS) [81]. Total lifetime duration of depression was
estimated in the depressed subjects using the life history methods
of Sheline [82] and Post [83], supplemented with information
derived from the SCID interview and the Antidepressant
Treatment History Form (ATHF) [84], which documents
depressive episode durations as well as durations of antidepressant
treatment, including the doses used and the treatment response.
Only periods of time during which subjects were actively
depressed (i.e., met DSM-IV criteria for MDD) were counted;
periods of time during which subjects were not depressed were not
included. Clinical history-taking and telomere assays were
performed blind to each other.
Assays
Telomere Length. High molecular weight DNA was
extracted from frozen whole blood using commercially available
reagents (Puregene, Gentra Systems, Qiagen, Valencia, CA). DNA
quality and quantity were assessed with a nanodrop
spectrophotometer and random samples were also assessed by
agarose gel electrophoresis. The telomere length measurement
assay was adapted from the published original method [85].
Briefly, the T (telomeric) and S (single copy gene) values of each
sample were determined by quantitative polymerase chain
reaction (PCR) using the following primers: tel1b [59-CGGTT-
T(GTTTGG)5GTT-39] and tel2b [59-GGCTTG(CCTTAC)-
5CCT-39] for T and hbg1 [59 GCTTCTGACACAACTGTGT-
TCACTAGC-39] and hbg2 [59-CACCAACTTCATCCA-
CGTTCACC-39] for S (human beta-globin). Genomic DNA
from HeLa cells was used as the reference to quantify the T and S
values relative to the reference DNA sample by the standard curve
method. All PCRs were carried out on a Roche Lightcycler 480
real-time PCR machine with 384-tube capacity (Roche
Diagnostics Corporation, Indianapolis, IN). The telomere
thermal cycling profile consisted of: cycling for T (telomeric)
PCR: denature at 96uC for 1 second, anneal/extend at 54uC for
60 seconds, with fluorescence data collection, 30 cycles; cycling for
S (single copy gene) PCR: denature at 95uC for 15 seconds, anneal
at 58uC for 1 second, extend at 72uC for 20 seconds, 8 cycles;
followed by denature at 96uC for 1 second, anneal at 58uC for 1
second, extend at 72uC for 20 seconds, hold at 83uC for 5 seconds
with data collection, 35 cycles. The inter-assay coefficient of
variation (CV) for telomere length measurement was 4%. Details
of the method can be found in [86].
Oxidative Stress. The recommended approach for
evaluating oxidative stress assesses the balance between anti-
oxidants and oxidative by-products, with assessment of at least one
antioxidant and one oxidized molecule [87,88,89]. Ascorbic acid
(Vitamin C) is often the preferred antioxidant to measure in this
context [87,88,89]. Although ascorbic acid is an essential nutrient
in humans (entirely derived from dietary consumption), ascorbic
acid levels reach steady state concentrations under fasting
conditions (approximately six hours following food consumption),
and they have been found to be relatively stable within individuals
across time and to predict long-term health outcomes up to 12
years later [90,91,92]. Because of this, and in order to limit the
problem of multiple hypothesis testing by examining oxidative by-
products and anti-oxidants separately, we a priori defined
‘‘oxidative stress’’ as the ratio of F2-isoprostanes [93,94,95] (a
class of major oxidative by-products) to ascorbic acid [89,96]. In a
prior study from our group, the ratio of oxidative by-products to
anti-oxidants was found to be inversely correlated with leukocyte
telomere length in stressed caregivers [58].
F2-isoprostanes (a collection of isomers) were measured by Dr.
Jason Morrow’s Lab at Vanderbilt University by gas chromatog-
raphy-mass spectrometry (GC-MS) as described previously.
[97,98]. The isoprostanes were extracted and purified with solid
phase extraction and thin layer liquid chromatography and then
converted to trimethylsilyl ether derivatives and analyzed by GC-
MS. Ascorbic acid was measured by Kronos Science Laboratory
using high performance liquid chromatagraphy (HPLC) method as
described previously [99]. Briefly, the serum sample was preserved
by adding an equal volume of metaphosphoric acid and treated
with dithiothreitol The resulting supernatant was injected into the
HPLC system equipped with diode array detector (DAD). The
separation was carried out using a 25064.6 mm Capcell Pak NH2
column (Shiseido, Tokyo, Japan) with a flow rate of 1 mL/min of
the mobile phases consisted of 10 mM ammonium acetate at
pH 4.2 and methanol. Ascorbic acid was quantified using external
standards with UV spectrophotometric detection at 243 nm
wavelength.
IL-6. Samples were collected in 10 ml serum separator tubes
(SST) tubes (Becton Dickinson, Franklin Lakes, NJ). Serum was
frozen and stored at – 80 C. A high sensitivity enzyme-linked
Telomere Length in Chronic Major Depression
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immunosorbent assay was used to quantify IL-6 concentrations
(R&D Systems, Minneapolis, MN). The assay sensitivity is ,0.1
pg/ml, and average intra- and inter-assay coefficients of variation
are 7% and 8% respectively. Each sample was analyzed in
duplicate according to manufacturer protocol. IL-6 assays were
performed in the lab of Dr. Firdaus Dhabhar at Stanford
University.
Statistical Methods
We first assessed the impact of age, sex, body-mass index (BMI),
and lifetime and current tobacco use as potential confounds; we
found significant effects of age and sex on telomere length, and
significant effects of age and BMI on IL-6 (data presented below).
Lifetime and current tobacco use were not significantly related to
any of these variables. Consequently, all analyses were controlled
for age and sex, and analyses involving IL-6 were additionally
controlled for BMI. Before analyzing the data, distributions were
examined for normality; non-normal distributions were natural log
transformed (Ln).
Between-group comparison of the demographic variables was
by independent sample t-tests, Chi square tests and independent
sample Kruskal-Wallis tests. Independent sample tests, rather than
paired sample tests, were used, since the absence of blood data in
one control subject (described above) resulted in unequal group
sizes. Other between-group data, when covariates were applied,
were analyzed by analysis of covariance (ANCOVA). Correlations
between variables were assessed by linear regression, or by
hierarchical linear regression, with age and sex (and BMI, in the
case of IL-6) entered first. All tests were 2-tailed with an alpha=
0.05.
Results
Demographics
The mean age of the depressed and control subjects did not
significantly differ (36.6611.8 [SD] vs. 36.8611.0 years [range
25–69 years], respectively), nor did the sex distribution (65%
female in each group), ethnicity distribution or body-mass index
(24.863.7 vs. 26.265.7 [kg/m(2)], respectively). The subject
groups also did not significantly differ in current and past alcohol
and nicotine consumption, marital status, highest educational level
attained or self-rated socioeconomic status [100], although mean
household income was significantly lower in the depressed subjects
than in the controls (t = 2.59, p,0.02, df = 32). Household income
was not significantly correlated with leukocyte telomere length (r =
0.13, ns, df = 25), IL-6 concentrations (r = 0.01, ns, df = 28) or the
oxidative stress ratio (r = 20.17, ns, df = 27). In addition, average
activity (exercise) levels per month, as measured by the Yale
Physical Activity Survey (YPAS) [101], were significantly lower in
the depressed sample than in the controls (t = 2.88, p,0.01), but
activity level was not significantly correlated with leukocyte
telomere length (r = 0.19, ns, df), IL-6 concentrations
(r =20.01, ns, df) or the oxidative stress ratio (r = 20.09, ns,
df). The mean 17-item Hamilton Depression Rating Scale (HDRS)
[81] rating in the depressed subjects was 19.363.9 (range 17–26),
and the mean chronicity of depression (i.e., lifetime months of
depression) was 156.56134.8 months (range 9.3–425.8 months).
The mean length of the current episode of depression was
125.16158.0 months (range 1.7–425.8 months). Demographic
characteristics of the subjects are provided in Table 1.
Telomere Length
Overall, leukocyte telomere length (in bp) was not significantly
different in the depressed subjects compared to the controls (mean
6 SD: depressed: 51016425 bp, vs. controls: 51416282 bp;
difference = 40 bp) (F = 0.17, ns [p = 0.66], controlling for age
and sex). The small average difference between the groups is
roughly equal to one year of accelerated aging at the level of the
leukocyte, assuming an average yearly attrition of 31–66 bp [58],
and given the measurement variance, this is not a meaningful
difference. We had predicted that not all depressed subjects would
be equally likely to show shortened telomeres, since the lifetime
exposure to depression varied greatly between subjects, and since
telomere length is believed to reflect cumulative history of cellular
reproduction and of exposure to cytotoxic stimuli such as
oxidation and inflammation and to stress. Therefore, as an a priori
planned comparison, we examined telomere length within the
depressed group as a function of cumulative lifetime duration of
depression, corrected for age and sex. Next, as a secondary
(exploratory) test of our hypothesis, we dichotomized lifetime
exposure to depression into a categorical independent variable,
comparing the control subjects (N= 17) to the depressed subjects
in the highest half of lifetime depression duration (n= 9), while
controlling for age and sex. Telomere length within the entire
depressed group was significantly inversely correlated with lifetime
depression duration (controlling for age and sex); individuals with
greater lifetime duration of major depression had significantly
shorter telomeres (F = 4.70, p,0.05) (Fig. 1). This relationship
remained statistically significant when lifetime and current tobacco
use and BMI were additionally controlled. When depressed
individuals in the upper half of lifetime exposure to depression
($9.2 years cumulative duration, n = 10) were compared to
controls, significant differences in telomere length were observed
(controls: 51416282 bp vs. depressed: 48606349 bp; difference =
Table 1. Characteristics of Depressed and Control Subjects.
Controls
n =17
Depressed
n=18 p
Age (Years) 36.6611.8 36.8611.0 ns
Sex (Female, %) 65% 67% ns
Ethnicity (%)
Caucasian
African-American
Asian
Other or Mixed
71%
18%
6%
5%
72%
17%
6%
5%
ns
Body-Mass Index (kg/m[2]) 24.863.7 26.365.9 ns
No Tobacco Ever (%) 59% 67% ns
Current Tobacco Use (%)
None
Sometimes
Daily
82%
12%
6%
83%
17%
0%
ns
Subjective Socio-economic
Status1
6.4561.13 5.7561.60 ns
Years of Education 15.8262.28 15.2862.06 ns
Annual Household Income
($)
$59,7756$32,550 $29,2256$26,005 ,0.02
Physical Activity Level2 3.1160.90 2.1061.26 ,0.01
1Subjective socioeconomic status was measured using a 10-rung ladder version
of the MacArthur Scale of Subjective Social Status [100], with higher numbers
equaling higher perceived socioeconomic status.
2Physical Activity Level was measured with the Yale Physical Activity Survey
(YPAS) [101]. On this scale, 1 = ‘‘not very active;’’ 2 = ‘‘weekend/vacations
only;’’ 3 = ‘‘more than 1–2 times per week;’’ 4 = ‘‘more than 3 times per week.’’
Other measures on the YPAS, such as ‘‘Vigorous Activity’’ and ‘‘Duration of
Vigorous Activity’’ yielded similar differences between groups.
doi:10.1371/journal.pone.0017837.t001
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281 bp; F= 2.87, p = 0.05, controlling for age and sex). This
difference also remained significant when lifetime and current
tobacco use and BMI were controlled. This difference in mean
telomere length (around 280 bp) is equivalent to approximately 7
years of ‘‘accelerated aging’’ at the level of the leukocyte. The fact
that this difference is significant after controlling for age suggests
that greater lifetime duration of depression was not simply a proxy
for older age, which is also associated with shorter telomeres.
In an exploratory analyses, we also assessed the relationship of
telomere length to the duration of the current major depressive
episode. The correlation was in the expected direction (with longer
episode duration associated with shorter telomeres), but this missed
statistical significance (r =20.44, p,0.09, controlling for age and
sex). We also examined the relationship of telomere length to
HDRS ratings and found no significant correlation (r =20.10,
p,0.80, controlling for age and sex). We also examined the
impact of antidepressant treatment on the relationship between
lifetime duration of depression and telomere length. Lifetime
exposure to untreated depression remained significantly inversely
correlated with telomere length (F = 3.62, p,0.05), but lifetime
exposure to depression while receiving antidepressants was not
(F = 2.50, p = 0.11). The latter relationship must be interpreted
cautiously, however, since the lengths of time subjects had
remained depressed while receiving antidepressant medication
spanned a relatively short range (range: 0 to 31.2 months).
Relationship of Telomere Length to Age and Sex by
Diagnosis
PBMC telomere length was significantly and inversely correlat-
ed with age (independently of sex) in the combined subject group
(r =20.36, p,0.05) and within the MDD group alone (r =20.58,
p = 0.01) but not within the control group alone (r =20.07, p =
0.79). Male, as opposed to female, gender was associated with
significantly longer PBMC telomere length (independently of age)
in the combined subject group (t = 2.09, p,0.05) and within the
control group alone (t = 2.27, p,0.05) but not within the MDD
group alone (t = 1.06, p = 0.30).
Oxidative Stress and Inflammation
There were no significant between-group differences in
measures of oxidative stress (F2-isoprostanes/Vit. C ratio)
(depressed: 0.01460.015; controls: 0.01060.010; F= 0.50, ns)
or inflammation (IL-6) (depressed: 0.8460.82 pg/ml; controls:
0.7360.37 pg/ml; F= 0.01, ns). Further, there were no significant
correlations between lifetime depression duration (controlling for
age and sex) and either the oxidative stress ratio (r =20.07, ns) or
IL-6 (r = 20.10, ns).
Relationship of Telomere Length to Oxidative Stress and
Inflammation
In the combined sample (depressed plus control subjects), the
oxidative stress ratio (F2-isoprostanes/Vitamin C) was significantly
inversely correlated with telomere length (F = 8.21, p,0.001,
controlling for age and sex) (Fig. 2). This relationship remained
significant in the separate depressed (F= 6.04, p,0.01) and
control groups (F = 4.38, p,0.05). Considering the components of
this ratio separately, Vitamin C concentrations were significantly
positively correlated with telomere length in the combined sample
(F = 4.72, p,0.01) as well as in the individual depressed (F= 5.85,
p,0.01) and control samples (F= 4.04, p,0.05) (all controlled for
age and sex). F2-isoprostane concentrations were significantly
negatively correlated with telomere length in the combined sample
(F = 4.78, p,0.01, controlling for age and sex), but this
relationship was only marginally significant in the separate
Figure 1. Relationship between cumulative lifetime duration of
depression and leukocyte telomere length (in base pairs, bp).
(F = 4.70, p,0.05, controlling for age and sex by hierarchical linear
regression).
doi:10.1371/journal.pone.0017837.g001
Figure 2. Relationship between the oxidative stress ratio (F-2
isoprostanes/Vitamin C concentrations, Ln transformed) and
leukocyte telomere length (in base pairs, bp). Filled circles
represent depressed subjects (‘‘MDD’’) (F = 6.04, p,0.01, controlling for
age and sex), and open squares represent controls (‘‘Cont’’) (F = 4.38,
p,0.05, controlling for age and sex). In the combined sample
(depressed plus controls), the relationship was also statistically
significant (F = 8.21, p,0.001, controlling for age and sex).
doi:10.1371/journal.pone.0017837.g002
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depressed (F= 2.59, p,0.10) and control groups (F = 2.31, p =
0.13) due to low statistical power. IL-6 concentrations were
significantly inversely correlated with telomere length in the
depressed group (F= 3.29, p,0.05, controlling for age, sex and
BMI) (Fig. 3), but not in the control group (F = 2.28, p = 0.13). In
the combined sample, this relationship approached statistical
significance (F = 2.45, p = 0.07, controlling for age, sex and BMI).
After controlling for lifetime duration of depression, the relation-
ships between the oxidative stress ratio and IL-6 concentrations
and telomere length remained significant (F= 4.91, p,0.02, and
F= 3.46, p,0.05, respectively).
Discussion
Across a broad range of depressive chronicity, depressed
individuals did not significantly differ from controls in leukocyte
telomere lengths. However, individuals with more chronic courses
of major depression had significantly shorter leukocyte telomeres
than healthy controls, suggesting this may be a cumulative marker
of chronic depression. Importantly, the relationship between
telomere length and lifetime duration of depression was significant
after age was controlled, indicating that longer exposure to
depression was not simply a proxy for more advanced age, which
is also associated with telomere shortening. Since telomere length
has been proposed as a biomarker of cell aging and a predictor of
health and longevity [38,41,42,46,47], this finding may underlie
some of the excess medical morbidity and premature mortality
seen in chronically depressed populations [1,2,3,4,5,6,7,8,9,10,11].
Depressed individuals with less chronic courses, however, showed
no significant differences in telomere length, compared to controls.
This argues against short telomeres representing a pre-existing risk
factor for, or an invariant concomitant of, major depression.
Rather, it suggests that telomere shortening may progress with
longer exposure to depression. Prospective studies will be needed
to explore this as well as the question of whether antidepressant
treatment can attenuate this shortening.
Our finding that telomere shortening is directly related to the
chronicity of depression exposure is similar to the finding of Epel
et al. in caregivers [58]. Although there are clear differences
between major depression and psychological stress, they, too,
found that telomere shortening was directly correlated with the
chronicity of caregiver stress, The study of affectively ill subjects by
Simon et al. [55] found a significant shortening of telomere length
in their whole affectively ill sample rather than in just a chronic
subgroup, as we did. However, it is important to note that the
average lifetime duration of affective illness in their depressed
sample was 31.8 611.2 years, compared to the average lifetime
duration of 13.0611.2 years in our sample. Accordingly, the
estimate of accelerated aging in our more chronically depressed
individuals is in line with the data from that study. One other study
of telomere length in MDD did not state the chronicity of its
sample [60]. The only prior study that did examine leukocyte
telomere length as a function of lifetime depression did not find a
significant relationship [61], but those data may not be
comparable to ours, since they did not exclude periods of time
during which subjects were not depressed that occurred after the
first onset of MDD, and since medical illnesses and various
neuropsychiatric conditions were not excluded [61].
The degree of telomere shortening we observed in the more
chronically depressed individuals (those above the median of
chronicity) corresponds to approximately seven years of ‘‘acceler-
ated cell aging.’’ This degree of ‘‘acceleration,’’ accords fairly well
with that described in stressed maternal caregivers (9–17 years)
[58], in combined spousal and offspring caregivers (4–8 years)
[59], and in depressed/affectively ill individuals (6 to 10+ years)
[55,61], assuming an average annual rate of telomere bp attrition
of 31–66 (although some estimates suggest annual attrition rates of
only 19–25 bp [59,61]). While shortened telomere length in
chronic depression is consistent with findings in other chronically
stressed and depressed populations [55,58,59,61,102], this mea-
sure is not specific to chronic stress or depression and thus is not
useful as a specific diagnostic ‘‘biomarker.’’
While the mediating biochemical factors responsible for telomere
shortening in chronic depression cannot be adequately assessed in a
cross-sectional study, our findings of significant inverse correlations
between telomere length and oxidative and inflammatory stress in
the depressed subjects raise the possibility that these biochemical
stressors contribute to telomere shortening in chronic depression.
However, the direction of causality is not fully clear, as cells with
shortened telomeres hyper-secrete pro-inflammatory cytokines
[28,103]. We found that oxidative stress was inversely correlated
with telomere length in the depressed subjects and the controls,
consistent with the reported shortening effect of oxidation on
telomeres [36,37,38,57,104]. IL-6 concentrations were inversely
correlated with telomere length in the depressed subjects but not in
the controls. The reasons for this difference are unknown. It may be
related to our small sample sizes, or to differences in specific
relationships between inflammatory and anti-inflammatory cyto-
kines in depressed individuals vs. controls [71]. The lack of
significant correlations between lifetime depression duration and
both the oxidative stress ratio and IL-6 does not argue against the
mechanistic hypothesis we put forward, since the hypothesis does
not require that oxidative stress and inflammation be progressive
across the life course of MDD. The lack of significant between-
group differences in oxidation and inflammation, measured cross-
sectionally, also does not argue against our mechanistic hypothesis.
Although speculative, it is possible that depressed individuals are
more sensitive to the telomere-shortening effects of oxidation and
Figure 3. Relationship between serum IL-6 concentrations (pg/
ml) and leukocyte telomere length (in base pairs, bp) in
depressed subjects. (F = 3.29, p,0.05, controlling for age, sex and
BMI). The relationship missed significance in the combined sample
(depressed plus controls) (F = 2.45, p = 0.07, controlling for age, sex and
BMI) and was not significant in the controls alone (not plotted) (F =
2.28, p = 0.13, controlling for age, sex and BMI).
doi:10.1371/journal.pone.0017837.g003
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inflammation due to some other biochemical ‘‘co-factor,’’ or due to
a lack of counter-regulatory anti-oxidant and anti-inflammatory
activities. Regarding the first possibility, emerging studies are
suggesting enhanced susceptibility of cells from depressed individ-
uals to apoptosis [105]. Regarding the second possibility, we and
others previously reported significantly low serum IL-10 levels in
MDD [71,106], along with an elevated IL-6/IL-10 ratio in MDD,
despite no significant elevations in serum IL-6 levels [71]. IL-10 is
an anti-inflammatory/immuno-regulatory cytokine, and data from
that study suggested a perturbed balance between pro- and anti-
inflammatory activity in MDD [71]. Similarly, studies have
previously shown not only increased oxidative activity in MDD,
but decreased counter-regulatory anti-oxidant activity [107,108,
109,110] in MDD.
Our findings, along with the literature reviewed below, suggest
that chronic inflammation and oxidation may be mechanisms by
which chronic depression can result in shortened telomeres.
Significant increases in oxidative stress [62,63,65,66,67] and
inflammatory stress [16,17,71,72,111,112] have been described in
many, but not all, studies of major depression. To the extent
oxidative and inflammatory stress are chronically increased in
depressed individuals, or to the extent depressed individuals are
more sensitive to such cytotoxic stimuli or have a compromised
ability to recover from oxidative or inflammatory damage, these
stressors could contribute to telomere shortening [113,114,115,
116]. Conversely, leukocyte telomere shortening, resulting in
immunosenescence and impaired leukocyte function, can lead to
increased inflammatory cytokine output [28] and to increased
oxidative stress [115], thus forming a vicious cycle [16]. The
significant correlations we observed between oxidative and
inflammatory stress and telomere length have not been previously
reported in individuals with MDD, but they are consistent with
relationships between oxidative and inflammatory stress and
telomere length in other populations. It is possible that leukocyte
telomere shortening occurs across conditions that are characterized
by chronic exposure to oxidation and/or inflammation or by
increased leukocyte turnover [49,58,59,117,118,119,120].
Limitations
The major strengths of the present study are the use of physically
healthy, well characterized, matched subjects, the prospective
recruitment, the assessment of important covariates such as BMI,
exercise and nicotine consumption, the exclusion of psychotropic
and other medications that might have influenced our results, the
assessment of depressive chronicity and the assessment of potential
biochemical mediators. The major limitations are the small sample
size, the use of self report to assess lifetime depression duration and
the lack of longitudinal data. While the failure to discern an overall
effect of depression (independent of chronicity) on telomere length
may be due to the lesser chronicity of our sample compared to others
[55], it is also possible that our small sample size lacked the statistical
power to detect the effect. The effect size (Cohen’s d) of telomere
differences in the study by Simon et al. [55] was 0.74, in the study by
Lung et al. [60] was 0.83, and in the study by Hartmann et al. [61]
was 0.59 (effect sizes calculated from published data). The sample
size used in the present study would have had between 40% –66%
power to detect effects of these magnitudes. Due to our small sample
size, especially the size of the sub-sample of depressed subjects with
more chronic depressions, our results should be considered
preliminary and in need of replication with a larger sample. There
are several additional caveats in interpreting our data. First, the
relationship between peripherally-measured inflammation and
oxidation and such processes in the central nervous system is
complex [121,122,123,124,125,126], and we make no extrapolation
of our results to CNS oxidation or inflammation. It should be noted,
however, that telomere length is reduced in hippocampal CA1
neurons in Alzheimer’s disease, and this has been postulated to
result, at least in part, from oxidative stress [127]. Second, it is not
known whether telomere length observed in leukocytes is related to
telomere length in other cell types or tissues [128], including the
central nervous system [129]. However, shortened telomeres in
peripheral blood leukocytes were significantly correlated with smaller
hippocampal volumes and with declining cognitive function among
participants in the Nurses’ Health Study [130]. The effects of
depression on telomere lengths of specific leukocyte subpopulations
and on specific tissues should be examined in future studies. Third, it
remains to be determined if our observed telomere length findings
represent changes on a per-cell basis or, rather, differences in the
relative proportions of circulating blood cell types, since subpopu-
lations of leukocytes (e.g., CD8+CD28- leukocytes) differ in average
telomere lengths [131]. It will be important in future studies to
determine which specific leukocyte subpopulations are mediating the
observed effects. Lastly, since childhood adversity (e.g., childhood
sexual abuse) is associated with shortened telomeres [132,133,134],
and since childhood adversity is more common in depressed
populations than in controls, such factors could have impacted our
data, independent of the effects of depression.
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